AssetMark’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
AssetMark's RPRX Position: Q3 2026 in Review
AssetMark increased its Royalty Pharma (RPRX) stake by 187% in Q3 2026, buying an estimated $1.2M and bringing the position to 31,155 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #976.
AssetMark first reported a position in RPRX in Q3 2022 and has held it in 11 quarters since. 573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.
- AssetMark held 31,155 shares of Royalty Pharma worth $1.82M as of Q3 2026.
- AssetMark bought 20,285 Royalty Pharma shares in Q3 2026, an estimated $1.2M.
- Royalty Pharma made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #976 holding.
- AssetMark first reported a position in Royalty Pharma in Q3 2022 and has held it in 11 quarters since.
- 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.